Drug intelligence / Profile preview

KK8123

Development stage: Phase 2
Lead developer: Kyowa Kirin
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

KK8123 is an investigational monoclonal antibody developed by Kyowa Kirin for the treatment of X-linked hypophosphatemia (XLH) and related hypophosphatemic disorders. It acts as an antagonist of fibroblast growth factor 23 (FGF23), a hormone involved in phosphate metabolism. By inhibiting FGF23, KK8123 aims to increase blood phosphorus levels and improve symptoms associated with XLH, such as bone disease and metabolic abnormalities. The drug is administered via subcutaneous injection and is currently being evaluated in Phase 1/2 clinical trials for safety, tolerability, pharmacokinetics, and pharmacodynamics in adults with XLH.

Targets

FGF23 (Fibroblast growth factor 23)

Beyond the preview

Go deeper on KK8123.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KK8123.

Explore the full profile